HIV is considered an epidemic, however, the rates of transmission of infection could be substantially reduced with a drug called Truvada®, a combination antiviral of Tenofovir Disoproxil Fumarate and Emtricitabine. By the CDC’s estimation regarding sexual and drug use behaviors among the U.S. population, 1.2 million individuals are eligible for Pre-Exposure Prophylaxis (PrEP), yet only about 80,000 individuals have been prescribed PrEP since the Food and Drug Administrations approved its use in 2012. To date, PrEP initiation and adoption has not been sufficient to have a large effect on HIV incidence. Further, research has shown that only a fraction of U.S. health care providers report having ever prescribed PrEP. The benefits of educating providers regarding the utilization of PrEP and encouraging them to incorporate the treatment into the care of their patients amounts to potentially reducing an epidemic, increasing the quality of life and saving lives
Bishop, Andrea M.
"Eliminating Clinician Fears to Prescribing Pre-Exposure Prophylaxis for Human Immunodeficiency Virus,"
Lynchburg Journal of Medical Science: Vol. 2
, Article 7.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol2/iss3/7
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.